Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 2569 | 2.03 |
09:36 ET | 100 | 2.07 |
09:38 ET | 1100 | 2.03 |
09:41 ET | 646 | 2.01 |
09:43 ET | 200 | 2.0001 |
09:45 ET | 407 | 2.03 |
09:48 ET | 600 | 2.03 |
09:52 ET | 100 | 2.04 |
09:54 ET | 7045 | 2.05 |
09:56 ET | 100 | 2.05 |
09:57 ET | 700 | 2.04 |
09:59 ET | 1204 | 2.05 |
10:03 ET | 100 | 2.045 |
10:06 ET | 100 | 2.04 |
10:10 ET | 1404 | 2.04 |
10:12 ET | 996 | 2.04 |
10:15 ET | 1945 | 2.05 |
10:19 ET | 900 | 2.04 |
10:21 ET | 795 | 2.0428 |
10:24 ET | 1307 | 2.07 |
10:26 ET | 100 | 2.07 |
10:32 ET | 100 | 2.06 |
10:33 ET | 14019 | 2.03 |
10:35 ET | 100 | 2.025 |
10:44 ET | 824 | 2.05 |
10:48 ET | 1275 | 2.03 |
10:50 ET | 200 | 2.02 |
10:51 ET | 600 | 2.02 |
10:55 ET | 100 | 2 |
10:57 ET | 100 | 2.01 |
11:00 ET | 300 | 2.01 |
11:02 ET | 100 | 2.02 |
11:04 ET | 200 | 2.02 |
11:06 ET | 470 | 2.02 |
11:08 ET | 1950 | 1.99 |
11:09 ET | 1600 | 1.98 |
11:11 ET | 100 | 1.975 |
11:13 ET | 100 | 1.98 |
11:15 ET | 994 | 1.99 |
11:18 ET | 3294 | 2.014287 |
11:20 ET | 200 | 2.02 |
11:24 ET | 100 | 2.02 |
11:26 ET | 200 | 2.025 |
11:27 ET | 100 | 2.03 |
11:29 ET | 7341 | 2 |
11:31 ET | 200 | 2 |
11:36 ET | 200 | 2 |
11:38 ET | 100 | 2 |
11:40 ET | 362 | 2.0101 |
11:42 ET | 1400 | 2.02 |
11:45 ET | 400 | 2.02 |
11:56 ET | 100 | 2.03 |
11:58 ET | 100 | 2.03 |
12:02 ET | 200 | 2.03 |
12:07 ET | 650 | 2.04 |
12:09 ET | 1600 | 2.05 |
12:12 ET | 200 | 2.045 |
12:14 ET | 636 | 2.0522 |
12:16 ET | 200 | 2.05 |
12:18 ET | 100 | 2.05 |
12:21 ET | 100 | 2.05 |
12:23 ET | 3000 | 2.04 |
12:25 ET | 2997 | 2.04 |
12:34 ET | 1850 | 2.06 |
12:38 ET | 912 | 2.07 |
12:39 ET | 700 | 2.06 |
12:52 ET | 100 | 2.07 |
12:54 ET | 1397 | 2.09 |
12:56 ET | 1900 | 2.1 |
12:57 ET | 1695 | 2.09 |
12:59 ET | 600 | 2.09 |
01:06 ET | 502 | 2.09 |
01:08 ET | 100 | 2.085 |
01:10 ET | 1300 | 2.07 |
01:12 ET | 400 | 2.08 |
01:15 ET | 2500 | 2.04 |
01:17 ET | 3988 | 2.035 |
01:19 ET | 200 | 2.05 |
01:21 ET | 400 | 2.04 |
01:24 ET | 1525 | 2.03 |
01:26 ET | 1300 | 2.03 |
01:28 ET | 200 | 2.02 |
01:33 ET | 779 | 2.025 |
01:35 ET | 6303 | 2 |
01:37 ET | 200 | 2.005 |
01:39 ET | 100 | 2.01 |
01:42 ET | 110 | 2.01 |
01:46 ET | 2089 | 2 |
01:53 ET | 2700 | 2.01 |
01:57 ET | 3150 | 2 |
02:00 ET | 5450 | 2.0017 |
02:02 ET | 7115 | 2 |
02:06 ET | 3000 | 1.9986 |
02:08 ET | 3700 | 2 |
02:09 ET | 200 | 2 |
02:13 ET | 1985 | 2 |
02:22 ET | 720 | 2.01 |
02:26 ET | 1002 | 2.01 |
02:27 ET | 4165 | 2.01 |
02:31 ET | 100 | 2.02 |
02:36 ET | 642 | 2.02 |
02:38 ET | 200 | 2.03 |
02:40 ET | 1517 | 2.01 |
02:42 ET | 721 | 2.02 |
02:44 ET | 800 | 2.02 |
02:45 ET | 500 | 2.03 |
02:47 ET | 100 | 2.02 |
02:56 ET | 400 | 2.03 |
02:58 ET | 200 | 2.04 |
03:00 ET | 200 | 2.05 |
03:02 ET | 200 | 2.05 |
03:03 ET | 943 | 2.04 |
03:05 ET | 1518 | 2.05 |
03:07 ET | 1883 | 2.045 |
03:09 ET | 1569 | 2.04 |
03:12 ET | 200 | 2.03 |
03:16 ET | 400 | 2.05 |
03:18 ET | 100 | 2.05 |
03:20 ET | 815 | 2.05 |
03:21 ET | 800 | 2.05 |
03:23 ET | 127 | 2.05 |
03:25 ET | 200 | 2.05 |
03:27 ET | 500 | 2.05 |
03:30 ET | 1674 | 2.05 |
03:32 ET | 500 | 2.05 |
03:34 ET | 2071 | 2.04 |
03:38 ET | 1637 | 2.03 |
03:39 ET | 100 | 2.025 |
03:41 ET | 400 | 2.04 |
03:45 ET | 3056 | 2.04 |
03:48 ET | 100 | 2.02 |
03:50 ET | 200 | 2.03 |
03:52 ET | 2000 | 2.04 |
03:54 ET | 510 | 2.04 |
03:56 ET | 4722 | 2.04 |
03:57 ET | 5282 | 2.05 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 113.9M | -1.1x | --- |
X4 Pharmaceuticals Inc | 112.8M | 7.4x | --- |
Rani Therapeutics Holdings Inc | 115.4M | -1.9x | --- |
Nuvectis Pharma Inc | 117.3M | -4.9x | --- |
Skye Bioscience Inc | 118.6M | -0.9x | --- |
Adicet Bio Inc | 118.7M | -0.6x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $113.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.47 |
EPS | $-1.80 |
Book Value | $5.64 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.